The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA FDA Announces Change in Status of 12 Peptides SSRP Institute Nine Anticipated FDA Approvals for January 2026 Guideline Central